Tag Archive for: cancer immunotherapy
CD-001: A Promising Novel Dual-Targeting Immunotherapy
/in Immunotherapy, Preclinical Research/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Molecule Boosts Vaccine Power Against Cancer and Viruses, In Vivo Study
/in Immunotherapy, Preclinical Research/by MaxFOR46: New Experimental Therapy Shows Tumor Shrinkage in Advanced Prostate Cancer Patients
/in Clinical Trial, Metastatic, Phase 1/by MaxAI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxIn The UK, Regulators Move Towards a New Era of Personalized Cancer Treatment
/in Expert Insights/by MaxHydrogel Breakthrough May Improve Cancer Vaccines
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Phase 3 Trial For Opevesostat A CYP11A1 Inhibitor in mCRPC January 20, 2026
- Newsletter 3/2026 January 18, 2026
- A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer January 16, 2026
- SL-28 Phase 1/2 Trial: A Potential Breakthrough for Advanced Solid Tumors January 16, 2026